Cargando…
Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience
We describe our institutional experience of developing a liquid biopsy approach using circulating tumor DNA (ctDNA) analysis for personalized medicine in cancer patients, focusing on the hurdles encountered during the multistep process in order to benefit other investigators wishing to set up this t...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692455/ https://www.ncbi.nlm.nih.gov/pubmed/36579573 http://dx.doi.org/10.3390/jpm12111845 |
_version_ | 1784837270720741376 |
---|---|
author | Chen, Michelle Jian, Damon Sidorov, Maxim Woo, Rinette W. L. Kim, Angela Stone, David E. Nazarian, Ari Nosrati, Mehdi Ice, Ryan J. de Semir, David Dar, Altaf A. Luštrik, Roman Kokošar, Janez Ausec, Luka Rowbotham, Michael C. Tranah, Gregory J. Kashani-Sabet, Mohammed Soroceanu, Liliana McAllister, Sean D. Desprez, Pierre-Yves |
author_facet | Chen, Michelle Jian, Damon Sidorov, Maxim Woo, Rinette W. L. Kim, Angela Stone, David E. Nazarian, Ari Nosrati, Mehdi Ice, Ryan J. de Semir, David Dar, Altaf A. Luštrik, Roman Kokošar, Janez Ausec, Luka Rowbotham, Michael C. Tranah, Gregory J. Kashani-Sabet, Mohammed Soroceanu, Liliana McAllister, Sean D. Desprez, Pierre-Yves |
author_sort | Chen, Michelle |
collection | PubMed |
description | We describe our institutional experience of developing a liquid biopsy approach using circulating tumor DNA (ctDNA) analysis for personalized medicine in cancer patients, focusing on the hurdles encountered during the multistep process in order to benefit other investigators wishing to set up this type of study in their institution. Blood samples were collected at the time of cancer surgery from 209 patients with one of nine different cancer types. Extracted tumor DNA and circulating cell-free DNA were sequenced using cancer-specific panels and the Illumina MiSeq machine. Almost half of the pairs investigated were uninformative, mostly because there was no trackable pathogenic mutation detected in the original tumor. The pairs with interpretable data corresponded to 107 patients. Analysis of 48 gene sequences common to both panels was performed and revealed that about 40% of these pairs contained at least one driver mutation detected in the DNA extracted from plasma. Here, we describe the choice of our overall approach, the selection of the cancer panels, and the difficulties encountered during the multistep process, including the use of several tumor types and in the data analysis. We also describe some case reports using longitudinal samples, illustrating the potential advantages and rewards in performing ctDNA sequencing to monitor tumor burden or guide treatment for cancer patients. |
format | Online Article Text |
id | pubmed-9692455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96924552022-11-26 Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience Chen, Michelle Jian, Damon Sidorov, Maxim Woo, Rinette W. L. Kim, Angela Stone, David E. Nazarian, Ari Nosrati, Mehdi Ice, Ryan J. de Semir, David Dar, Altaf A. Luštrik, Roman Kokošar, Janez Ausec, Luka Rowbotham, Michael C. Tranah, Gregory J. Kashani-Sabet, Mohammed Soroceanu, Liliana McAllister, Sean D. Desprez, Pierre-Yves J Pers Med Article We describe our institutional experience of developing a liquid biopsy approach using circulating tumor DNA (ctDNA) analysis for personalized medicine in cancer patients, focusing on the hurdles encountered during the multistep process in order to benefit other investigators wishing to set up this type of study in their institution. Blood samples were collected at the time of cancer surgery from 209 patients with one of nine different cancer types. Extracted tumor DNA and circulating cell-free DNA were sequenced using cancer-specific panels and the Illumina MiSeq machine. Almost half of the pairs investigated were uninformative, mostly because there was no trackable pathogenic mutation detected in the original tumor. The pairs with interpretable data corresponded to 107 patients. Analysis of 48 gene sequences common to both panels was performed and revealed that about 40% of these pairs contained at least one driver mutation detected in the DNA extracted from plasma. Here, we describe the choice of our overall approach, the selection of the cancer panels, and the difficulties encountered during the multistep process, including the use of several tumor types and in the data analysis. We also describe some case reports using longitudinal samples, illustrating the potential advantages and rewards in performing ctDNA sequencing to monitor tumor burden or guide treatment for cancer patients. MDPI 2022-11-04 /pmc/articles/PMC9692455/ /pubmed/36579573 http://dx.doi.org/10.3390/jpm12111845 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Chen, Michelle Jian, Damon Sidorov, Maxim Woo, Rinette W. L. Kim, Angela Stone, David E. Nazarian, Ari Nosrati, Mehdi Ice, Ryan J. de Semir, David Dar, Altaf A. Luštrik, Roman Kokošar, Janez Ausec, Luka Rowbotham, Michael C. Tranah, Gregory J. Kashani-Sabet, Mohammed Soroceanu, Liliana McAllister, Sean D. Desprez, Pierre-Yves Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience |
title | Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience |
title_full | Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience |
title_fullStr | Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience |
title_full_unstemmed | Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience |
title_short | Pitfalls and Rewards of Setting Up a Liquid Biopsy Approach for the Detection of Driver Mutations in Circulating Tumor DNAs: Our Institutional Experience |
title_sort | pitfalls and rewards of setting up a liquid biopsy approach for the detection of driver mutations in circulating tumor dnas: our institutional experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692455/ https://www.ncbi.nlm.nih.gov/pubmed/36579573 http://dx.doi.org/10.3390/jpm12111845 |
work_keys_str_mv | AT chenmichelle pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT jiandamon pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT sidorovmaxim pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT woorinettewl pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT kimangela pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT stonedavide pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT nazarianari pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT nosratimehdi pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT iceryanj pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT desemirdavid pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT daraltafa pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT lustrikroman pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT kokosarjanez pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT ausecluka pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT rowbothammichaelc pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT tranahgregoryj pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT kashanisabetmohammed pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT soroceanuliliana pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT mcallisterseand pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience AT desprezpierreyves pitfallsandrewardsofsettingupaliquidbiopsyapproachforthedetectionofdrivermutationsincirculatingtumordnasourinstitutionalexperience |